3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
5
Breast Neoplasms
5
Ureteral Neoplasms
4
Neoplasms
4
Urethral Neoplasms
2
Recurrence
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Dexamethasone
13
Bortezomib
8
Cyclophosphamide
6
Lenalidomide
4
pomalidomide
3
isatuximab
3
Kidney Transplantation
3
Calcium Dobesilate
3
glucarpidase
2
Thalidomide
2
Paclitaxel
2
Gemcitabine
2
Carboplatin
2
Bendamustine Hydrochloride
2
Azacitidine
2
vinflunine
1
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pevonedistat
1
pembrolizumab
1
osimertinib
1
mirabegron
1
melflufen
1
gamma-Glutamyl Hydrolase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Renal Insufficiency
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled